AndyForce to Participate in 'P Morgan Healthcare Conference' with CureBio

[Asia Economy Reporter Hyunseok Yoo] AndyForce announced on the 9th that its bio-subsidiary CureBio will participate in the 'JP Morgan Healthcare Conference 2020' held in San Francisco, USA, for four days starting from the 13th.

At this conference, CureBio plans to introduce its major pipelines based on the Aminoacyl-tRNA synthetase (ARS) platform, including kidney cancer, various anticancer treatments, disease therapeutics, and diagnostic kits. With numerous leading pharmaceutical and bio companies from Korea and abroad attending, the company intends to actively seek collaboration opportunities with global big pharma and institutional investors.

Celebrating its 38th year, the JP Morgan Healthcare Conference is the world's largest pharmaceutical and bio event where pharmaceutical bio companies and related investors from around the globe gather. Approximately 1,500 global companies from about 40 countries participate to showcase their pipelines, attract investments, discover partners, build networks, and understand the latest trends in the pharmaceutical and bio markets.

CureBio is developing peptide drugs based on the ARS (Aminoacyl tRNA Synthetase) protein, which detects diseases and maintains homeostasis in the human body. Currently, it is focusing on Phase 1 clinical trials of the peptide-based kidney cancer treatment Neopep GT and the hair loss treatment Neopep A1H.

CureBio's kidney cancer treatment Neopep GT is a new drug created by peptide-forming the GRS (Glycyl tRNA Synthetase) protein, which the human immune system uses to attack kidney cancer cells. The hair loss treatment Neopep A1H stimulates stem cells that induce hair growth to promote hair regeneration.

A company official stated, “Research results on the ARS platform have been published in multiple journals, including the September issue of Nature Reviews Cancer,” and added, “Active research is ongoing on CureBio’s hair loss treatment Neopep A1H and kidney cancer treatment Neopep GT, and through this JP Morgan conference, we plan to proceed with licensing-out discussions with global pharmaceutical companies.”